I-mab - Google Search

table,div,span,p{display:none}Please click here if you are not redirected within a few seconds.

AllNewsImages Videos Maps Books

I-Mab stock initiated with Buy rating at BTIG on gastric cancer drug potential

Investing.com - BTIG initiated coverage on I-Mab (NASDAQ:IMAB) with a Buy rating and a $7.00 price target, citing the potential of its...
12 hours ago

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination...
1 day ago

I-Mab to accelerate investment in givastomig (IMAB:NASDAQ)

I-Mab (NASDAQ:IMAB) said on Monday that it is accelerating investment in its lead drug candidate, givastomig, a bispecific antibody for...
1 day ago

I-Mab initiated with a Buy at BTIG

BTIG initiated coverage of I-Mab (IMAB) with a Buy rating and $7 price target The firm believes givastomig has “best-in-class potential” to...
14 hours ago

Major Cancer Drug Trial Expansion: I-Mab's Givastomig to Target Multiple GI Cancers in Global Study

I-Mab (NASDAQ: IMAB) announced significant expansion of its givastomig program, a CLDN18.2 x 4-1BB bispecific antibody for cancer treatment.
1 day ago

Is I Mab Depositary Receipt backed by strong institutional buying - July 2025 Outlook & Breakout Confirmation Trade Signals

Lancaster City Council

【Risk-Adjusted Returns】✌️Low investments, high profits! Start with $100 and earn consistent monthly income.
5 hours ago

I-Mab Accelerates Investment in Givastomig for Metastatic Gastric Cancers and Announces Leadership Changes

Quiver Quantitative

I-Mab announces investment in givastomig for metastatic gastric cancers, planning Phase 2 studies an.
1 day ago

BTIG Initiates I-MAB at Buy With $7 Price Target

I-MAB has an average rating of buy and mean price target of $6.67, according to analysts polled by FactSet. ... -September 09, 2025 at 07:26...
12 hours ago

Needham Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $6

Needhamanalyst Gil Blum maintains $I-Mab(IMAB.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a...
1 day ago

I-Mab Cuts 27% of Workforce After Pipeline Re-Prioritization

I-Mab will cut 27% of staff, weeks after announcing a reprioritization of its pipeline to focus on a Phase I bispecific antibody. The move will...
7 months ago